0000899243-21-039857.txt : 20211012
0000899243-21-039857.hdr.sgml : 20211012
20211012163047
ACCESSION NUMBER: 0000899243-21-039857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211008
FILED AS OF DATE: 20211012
DATE AS OF CHANGE: 20211012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mainolfi Nello
CENTRAL INDEX KEY: 0001821189
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 211318882
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 200 ARSENAL YARDS BLVD., SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-08
0
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821189
Mainolfi Nello
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
1
1
0
0
Chief Executive Officer
Common Stock
2021-10-08
4
M
0
41544
2.08
A
505743
D
Common Stock
2021-10-08
4
S
0
21236
55.5598
D
484507
D
Common Stock
2021-10-08
4
S
0
9369
56.8247
D
475138
D
Common Stock
2021-10-08
4
S
0
2078
57.2887
D
473060
D
Common Stock
2021-10-08
4
S
0
7920
59.2756
D
465140
D
Common Stock
2021-10-08
4
S
0
670
60.3165
D
464470
D
Common Stock
2021-10-08
4
S
0
271
61.87
D
464199
D
Common Stock
2021-10-11
4
M
0
6456
2.08
A
470655
D
Common Stock
2021-10-11
4
S
0
5712
53.5791
D
464943
D
Common Stock
2021-10-11
4
S
0
744
54.4979
D
464199
D
Stock Option (Right to Buy)
2.08
2021-10-08
4
M
0
41544
0.00
D
2029-11-13
Common Stock
41544
35181
D
Stock Option (Right to Buy)
2.08
2021-10-11
4
M
0
6456
0.00
D
2029-11-13
Common Stock
6456
28725
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.10 to $56.09. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.19 to $57.185. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.20 to $58.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.90 to $59.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.91 to $60.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.19 to $54.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.28 to $54.60. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The shares underlying this stock option shall vest upon the achievement of specified performance-based milestones.
/s/ Bruce Jacobs, as Attorney-in-Fact
2021-10-12